The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer
Open accessAbstract
Summary Pancreatic cancer has a dismal prognosis as cancer-specific symptoms occur only at an advanced stage. If the cancer is to be discovered early, it will have to be done in asymptomatic individuals. Since the incidence of pancreatic cancer is low, screening for asymptomatic cancer in the general population will not be feasible. Screening will have to be restricted to subjects at high risk for pancreatic cancer. The proportion of pancreatic cancer patients who also have hyperglycemia or diabetes has previously been under appreciated; new data show that up to 80% are either hyperglycemic or diabetic and this can be evident in the pre-symptomatic phase. Diabetes improves following pancreatic cancer resection suggesting that diabetes is caused by the cancer. Conversely, older subjects with new-onset diabetes have an approximately 8 fold higher risk of having pancreatic cancer compared to the general population. Recognition of new-onset diabetes as an early manifestation of pancreatic cancer could lead to diagnosis of asymptomatic, early stage pancreatic cancer. However, primary type 2 diabetes is common and pancreatic cancer is relatively uncommon in the general population and the two forms of diabetes are clinically indistinguishable. The success of the strategy to use new-onset hyperglycemia and diabetes as a screening tool to identify subjects with a high likelihood of having asymptomatic pancreatic cancer will depend largely on our ability to differentiate pancreatic cancer-associated diabetes from the more common type 2 diabetes using a (serologic) biomarker.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Prevalence and Clinical Profile of Pancreatic Cancer–Associated Diabetes Mellitus
Pannala, R., Leirness, J. B., Bamlet, W. R., Basu, A., Petersen, G. M., & Chari, S. T. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.039 · Cited by 621
Self-citationCarbohydrate Metabolism in Non-Insulin-Dependent Diabetes Mellitus
Dinneen, S., Gerich, J., & Rizza, R. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271007 · Cited by 279
Cited by
Vigneri, P., Frasca, F., Sciacca, L., Pandini, G., & Vigneri, R. (2009) · Endocrine Related Cancer · doi:10.1677/erc-09-0087 · Cited by 1,009
Multicenter study of early pancreatic cancer in Japan
Kanno, A., Masamune, A., Hanada, K., Maguchi, H., Shimizu, Y., Ueki, T., Hasebe, O., Ohtsuka, T., Nakamura, M., Takenaka, M., et al. (2018) · Pancreatology · doi:10.1016/j.pan.2017.11.007 · Cited by 291
Liu, K.-L., Wu, T., Chen, P.-T., Tsai, Y. M., Roth, H., Wu, M.-S., Liao, W.-C., & Wang, W. (2020) · The Lancet Digital Health · doi:10.1016/s2589-7500(20)30078-9 · Cited by 222
Lead-time trajectory of CA19-9 as an anchor marker for pancreatic cancer early detection
Fahrmann, J. F., Schmidt, C. M., Mao, X., Irajizad, E., Loftus, M., Zhang, J., Patel, N., Vykoukal, J., Dennison, J. B., Long, J. P., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.11.052 · Cited by 208
Sharma, A., Smyrk, T. C., Levy, M. J., Topazian, M. A., & Chari, S. T. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.04.025 · Cited by 204
Wang, Z., Lai, S.-T., Xie, L., Zhao, J.-D., Ma, N.-Y., Zhu, J., Ren, Z.-G., & Jiang, G.-L. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.04.007 · Cited by 176
Prevalence of Diabetes Mellitus in Pancreatic Cancer Compared to Common Cancers
Aggarwal, G., Kamada, P., & Chari, S. T. (2013) · Pancreas · doi:10.1097/mpa.0b013e3182592c96 · Cited by 167
Self-citationPancreatic Cancer Prediction Through an Artificial Neural Network
Muhammad, W., Hart, G. R., Nartowt, B., Farrell, J. J., Johung, K., Liang, Y., & Deng, J. (2019) · Frontiers in Artificial Intelligence · doi:10.3389/frai.2019.00002 · Cited by 159
Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review
Kenner, B., Chari, S. T., Kelsen, D., Klimstra, D. S., Pandol, S. J., Rosenthal, M., Rustgi, A. K., Taylor, J. A., Yala, A., Abul-Husn, N., et al. (2021) · Pancreas · doi:10.1097/mpa.0000000000001762 · Cited by 158
Self-citationSerum biomarker signature-based liquid biopsy for diagnosis of early-stage pancreatic cancer
Mellby, L. D., Nyberg, A. P., Johansen, J. S., Wingren, C., Nordestgaard, B. G., Bojesen, S. E., Mitchell, B. L., Sheppard, B. C., Sears, R. C., & Borrebaeck, C. A. K. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6658 · Cited by 159
Diabetes and Pancreatic Cancer: Chicken or Egg?
Magruder, J. T., Elahi, D., & Andersen, D. K. (2011) · Pancreas · doi:10.1097/mpa.0b013e318209e05d · Cited by 140
Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study
Azoulay, L., Filion, K. B., Platt, R. W., Dahl, M., Dormuth, C. R., Clemens, K. K., Durand, M., Juurlink, D. N., Targownik, L. E., Turin, T. C., et al. (2016) · BMJ · doi:10.1136/bmj.i581 · Cited by 120
Maitra, A., Sharma, A., Brand, R. E., Van Den Eeden, S. K., Fisher, W. E., Hart, P. A., Hughes, S. J., Mather, K. J., Pandol, S. J., Park, W. G., et al. (2018) · Pancreas · doi:10.1097/mpa.0000000000001169 · Cited by 93
Self-citationQureshi, T. A., Gaddam, S., Wachsman, A. M., Wang, L., Azab, L., Asadpour, V., Chen, W., Xie, Y., Wu, B., Pandol, S. J., et al. (2022) · Cancer Biomarkers · doi:10.3233/cbm-210273 · Cited by 79
GLP ‐1 receptor agonists and the risk for cancer: A meta‐analysis of randomized controlled trials
Silverii, G. A., Marinelli, C., Bettarini, C., Del Vescovo, G. G., Monami, M., & Mannucci, E. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16489 · Cited by 67
Kang, M., Qin, W., Buya, M., Dong, X., Zheng, W., Lu, W., Chen, J., Guo, Q., & Wu, Y. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.12.031 · Cited by 63
Singh, D. P., Sheedy, S., Goenka, A. H., Wells, M., Lee, N. J., Barlow, J., Sharma, A., Kandlakunta, H., Chandra, S., Garg, S. K., et al. (2020) · Pancreatology · doi:10.1016/j.pan.2020.07.410 · Cited by 62
Self-citationWan, G., Sun, X., Li, F., Wang, X., Li, C., Li, H., Yu, X., & Cao, F. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000493214 · Cited by 57
Hart, P. A., Baichoo, E., Bi, Y., Hinton, A., Kudva, Y. C., & Chari, S. T. (2015) · Pancreatology · doi:10.1016/j.pan.2015.02.006 · Cited by 51
Self-citationHart, P. A., Andersen, D. K., Mather, K. J., Castonguay, A. C., Bajaj, M., Bellin, M. D., Bradley, D., Contreras, N., Habtezion, A., Korc, M., et al. (2018) · Pancreas · doi:10.1097/mpa.0000000000001168 · Cited by 46
Schwartz, N. R. M., Matrisian, L. M., Shrader, E. E., Feng, Z., Chari, S., & Roth, J. A. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.7798 · Cited by 43
Self-citationIs screening for pancreatic cancer in high-risk individuals one step closer or a fool's errand?
Hart, P. A., & Chari, S. T. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.09.024 · Cited by 32
Self-citationBaecker, A., Kim, S., Risch, H. A., Nuckols, T. K., Wu, B. U., Hendifar, A. E., Pandol, S. J., Pisegna, J. R., & Jeon, C. Y. (2019) · PLOS ONE · doi:10.1371/journal.pone.0218580 · Cited by 31
Early Detection of Pancreatic Cancer: The Role of Industry in the Development of Biomarkers
Kenner, B. J., Go, V. L. W., Chari, S. T., Goldberg, A. E., & Rothschild, L. J. (2017) · Pancreas · doi:10.1097/mpa.0000000000000939 · Cited by 24
Self-citationPancreatic Adenocarcinoma: Imaging Modalities and the Role of Artificial Intelligence
Anghel, C., Mugur, G. C., Anghel, D. A., Rusu-Munteanu, G. I., Dumitru, R. L., & Lupescu, I. G. (2024) · doi:10.20944/preprints202401.0904.v1 · Cited by 23
Metadata
- Authors
- Pannala, R., Basu, A., Petersen, G. M., & Chari, S. T.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2009-01
- Volume
- 10
- Issue
- 1
- Pages
- 88-95
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2155146717
- Cited by
- 558
- References
- 3
- FWCI
- 7.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
